点击显示 收起
Institute of Community Health Studies
New England Research Institutes
9 Galen Street
Watertown, MA 02472
E-mail: sharris{at}neri.org
Dear Sir:
In their recent case-control study, Stene et al (1) reported that the use of cod liver oil in the first year of life was associated with a reduced risk of type 1 diabetes, but that the use of other vitamin D supplements during the same period was not. This finding is in contrast with that of Hyppönen et al (2), who, in a prospective cohort study of the incidence of type 1 diabetes, found a strong, dose-dependent, protective effect of vitamin D supplements. Why this difference? One possibility is that vitamin D is protective only at relatively high doses. In the study by Hyppönen et al, few infants were given cod liver oil but >99% received some amount of vitamin D supplementation. For this reason, the reference group in dose-related analyses included infants receiving up to 50 µg/d, a dose 10 times that of the US recommendation (5 µg/d) (3). The risk of type 1 diabetes was sharply reduced at doses >50 µg/d. Stene et al did not collect information on individual doses of cod liver oil or other vitamin D supplements but did report that the manufacturers' recommended doses for both products was 10 µg/d. Thus, their data do not rule out a protective effect of vitamin D at doses >10 µg/d. The fact that they observed a protective effect of cod liver oil at the same dose is interesting, and, as they suggest, it may reflect an antiinflammatory effect of long-chain n-3 fatty acids. Certainly, the ability of both cod liver oil and other forms of supplemental vitamin D to prevent type 1 diabetes bears further investigation.
REFERENCES